Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
19.45B
Market cap19.45B
Price-Earnings ratio
13.73
Price-Earnings ratio13.73
Dividend yield
Dividend yield
Average volume
1.23M
Average volume1.23M
High today
$98.79
High today$98.79
Low today
$96.93
Low today$96.93
Open price
$97.52
Open price$97.52
Volume
939.38K
Volume939.38K
52 Week high
$112.29
52 Week high$112.29
52 Week low
$63.93
52 Week low$63.93

Stock Snapshot

The current Incyte(INCY) stock price is $97.34, with a market capitalization of 19.45B. The stock trades at a price-to-earnings (P/E) ratio of 13.73.

On 2026-05-27, Incyte(INCY) stock traded between a low of $96.93 and a high of $98.79. Shares are currently priced at $97.34, which is +0.4% above the low and -1.5% below the high.

The Incyte(INCY)'s current trading volume is 939.38K, compared to an average daily volume of 1.23M.

During the past year, Incyte(INCY) stock moved between $63.93 at its lowest and $112.29 at its peak.

During the past year, Incyte(INCY) stock moved between $63.93 at its lowest and $112.29 at its peak.

INCY News

Barchart 1d
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Barchart.com

...

Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Barchart.com
Simply Wall St 3d
A Look At Incyte Valuation As New AI Drug Discovery Partnerships Gain Traction

Incyte (INCY) has moved to deepen its use of artificial intelligence in drug discovery, broadening collaborations with Genesis Molecular AI and Edison Scientifi...

A Look At Incyte Valuation As New AI Drug Discovery Partnerships Gain Traction
Nasdaq 5d
Bernstein Initiates Coverage of Incyte with Market Perform Recommendation

Fintel reports that on May 22, 2026, Bernstein initiated coverage of Incyte (NasdaqGS:INCY) with a Market Perform recommendation. Analyst Price Forecast Sugges...

Bernstein Initiates Coverage of Incyte with Market Perform Recommendation

Analyst ratings

57%

of 30 ratings
Buy
36.7%
Hold
56.7%
Sell
6.7%

More INCY News

TipRanks 5d
Incyte’s Ruxolitinib Cream Delivers Strong Phase 3b Eczema Data, Supporting Dermatology Upside for INCY

Incyte (INCY) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel...

TipRanks 6d
Top Incyte Insider Makes Major Move With Fresh Stock Sale

New insider activity at Incyte ( (INCY) ) has taken place on May 21, 2026. Start a conversation with TipRanks’ trusted, data-backed investment intelligence As...

TipRanks 6d
Bernstein starts Incyte at MarketPerform, sees no clear path for revenue rebound

Bernstein initiated coverage of Incyte (INCY) with a Market Perform rating and $99 price target The firm is concerned that there is no clear pathway for revenue...

TipRanks 6d
Incyte initiated with a Market Perform at Bernstein

Bernstein initiated coverage of Incyte (INCY) with a Market Perform rating and $99 price target Published first on TheFly – the ultimate source for real-time,...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.